1-(3,5-Dihydroxyphenyl)-2-n-butylaminoethanol | 53500-91-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 酚类
• 英文名称: 1-(3,5-Dihydroxyphenyl)-2-n-butylaminoethanol
• 英文别名: 5-[2-(Butylamino)-1-hydroxyethyl]benzene-1,3-diol
• CAS: 53500-91-7
• 化学式: C₁₂H₁₉NO₃
• 分子量: 225.288
• InChiKey: MWDOQDUKHAQJIQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  16
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  72.7
• 氢给体数：
  4
• 氢受体数：
  4

文献信息

• [EN] COMPOUNDS FOR THE TREATMENT OF HYPERGLYCAEMIA<br/>[FR] COMPOSÉS POUR LE TRAITEMENT DE L'HYPERGLYCÉMIE
  申请人：ATROGI AB

  公开号：WO2017153737A1

  公开（公告）日：2017-09-14

  There is herein provided a compound of formula (I) or a pharmaceutically acceptable salt thereof, for use in the treatment of hyperglycaemia or a disorder characterized by hyperglycaemia, such as type 2 diabetes, wherein X, R1, R2, R3 and n have meanings as provided in the description.

  本文提供了一种式（I）的化合物或其在药学上可接受的盐，用于治疗高血糖或高血糖症状的疾病，如2型糖尿病，其中X，R1，R2，R3和n的含义如描述中所提供。
• [EN] BETA-HYDROXYETHYLAMINES FOR USE IN THE TREATMENT OR PREVENTION OF NON-ALCOHOLIC FATTY LIVER DISEASES<br/>[FR] BÊTA-HYDROXYÉTHYLAMINES POUR UTILISATION DANS LE TRAITEMENT OU LA PRÉVENTION DES STÉATOSES HÉPATIQUES NON ALCOOLIQUES
  申请人：ATROGI AB

  公开号：WO2019053428A1

  公开（公告）日：2019-03-21

  There is herein provided a compound of formula (I) or a pharmaceutically acceptable salt thereof, for use in the treatment of a non-alcoholic fatty liver disease (NAFLD), such as non-alcoholic steatohepatitis (NASH), wherein X, R1, R2, R3 and n have meanings as provided in the description.

  本文提供了一种化合物（I）或其药用可接受盐，用于治疗非酒精性脂肪肝病（NAFLD），如非酒精性脂肪性肝炎（NASH），其中X、R1、R2、R3和n的含义如描述中所提供。
• COMPOUNDS FOR THE TREATMENT OF HYPERGLYCAEMIA
  申请人：Atrogi AB

  公开号：EP3426239A1

  公开（公告）日：2019-01-16
• Respiratory Drug Condensation Aerosols and Methods of Making and Using Them
  申请人：Hale Ron L.

  公开号：US20090258075A1

  公开（公告）日：2009-10-15

  Described herein are respiratory drug condensation aerosols and methods of making and using them. Kits for delivering condensation aerosols are also described. The respiratory drug aerosols typically comprise respiratory drug condensation aerosol particles. In some variations the respiratory drug compound is selected from the group consisting of β-adrenergics, methylxanthines, anticholinergics, corticosteroids, mediator-release inhibitors, anti-leukotriene drugs, asthma inhibitors, asthma antagonists, anti-endothelin drugs, prostacyclin drugs, ion channel or pump inhibitors, enhancers, or modulators and pharmaceutically acceptable analogs, derivatives, and mixtures thereof. Methods of treating a respiratory ailment using the described aerosols are also described. In general, the methods typically comprise the step of administering a therapeutically effective amount of respiratory drug condensation aerosol to a person with a respiratory ailment. Methods of forming a respiratory drug condensation aerosol are also described. The methods comprise the steps of vaporizing and condensing a respiratory drug composition.
• US4814174A
  申请人：——

  公开号：US4814174A

  公开（公告）日：1989-03-21